



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

October 19, 2022

Chee Kong Choo  
Director and Chairman  
CytoMed Therapeutics Pte. Ltd.  
21 Bukit Batok Crescent  
#17-80 WCEGA Tower  
Singapore 658065

**Re: CytoMed Therapeutics Pte. Ltd.  
Amendment No. 3 to Draft Registration Statement on Form F-1  
Submitted September 30, 2022  
CIK No. 0001873093**

Dear Chee Kong Choo:

We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments.

Amendment No. 3 to Draft Registration Statement on Form F-1 Submitted September 30, 2022

Business

Overview, page 89

1. We note the revisions in timing to your product candidate pipeline. Revise the associated disclosure to clarify your plans with respect to the revised timetables.

You may contact Tracie Mariner at (202) 551-3744 or Daniel Gordon at (202) 551-3486 if you have questions regarding comments on the financial statements and related matters. Please contact Abby Adams at (202) 551-6902 or Celeste Murphy at (202) 551-3257 with any other questions.

Sincerely,

Chee Kong Choo  
CytoMed Therapeutics Pte. Ltd.  
October 19, 2022  
Page 2

Division of Corporation Finance  
Office of Life Sciences

cc: Richard I. Anslow, Esq.